HC Wainwright Issues Negative Outlook for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.04. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at ($0.01) EPS and FY2027 earnings at $0.14 EPS.

Protalix BioTherapeutics Stock Down 4.0%

Shares of NYSE:PLX opened at $2.14 on Monday. The company has a market cap of $172.42 million, a P/E ratio of -16.46 and a beta of -0.26. The business has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $2.21. Protalix BioTherapeutics has a 52 week low of $1.32 and a 52 week high of $3.19.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLX. R Squared Ltd purchased a new position in shares of Protalix BioTherapeutics during the 4th quarter worth about $26,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Protalix BioTherapeutics in the second quarter valued at approximately $27,000. SG Americas Securities LLC acquired a new position in Protalix BioTherapeutics during the fourth quarter worth approximately $31,000. Bank of America Corp DE increased its position in Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after purchasing an additional 21,886 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Protalix BioTherapeutics during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.